Total trials
1,019
Active
127
Phase 3
331
Total enrollment
4,004,665
Pipeline matrix
Showing 40 of 79 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Vedolizumab IV | — | — | 11 | ||||
| Vedolizumab | — | 26 | |||||
| Brentuximab Vedotin | — | — | 11 | ||||
| Vedolizumab SC | — | — | — | 9 | |||
| Doxorubicin | — | — | — | 4 | |||
| Vinblastine | — | — | — | 3 | |||
| Dacarbazine | — | — | — | 3 | |||
| Adalimumab | — | — | — | 4 | |||
| Fruquintinib | — | — | — | — | — | 1 | |
| Tofacitinib | — | — | — | — | — | 1 | |
| Ustekinumab | — | — | — | — | — | 1 | |
| Zasocitinib | — | — | — | 10 | |||
| Elritercept | — | — | — | — | 5 | ||
| TAK-279 | — | — | — | 12 | |||
| Mezagitamab | — | — | — | 6 | |||
| TAK-360 | — | — | — | — | 4 | ||
| Fazirsiran | — | — | — | — | 4 | ||
| Maribavir | — | — | — | 5 | |||
| TDV | — | — | — | 11 | |||
| TAK-861 | — | — | — | — | 5 | ||
| TAK-788 | — | — | — | 4 | |||
| ADVATE | — | — | — | — | — | 2 | |
| Prednisone | — | — | — | — | 2 | ||
| TAK-881 | — | — | — | 7 | |||
| Teduglutide | — | — | — | — | 4 | ||
| TAK-755 | — | — | — | 4 | |||
| vonicog alfa | — | — | — | — | 2 | ||
| Methotrexate | — | — | — | 7 | |||
| Elaprase | — | — | — | 4 | |||
| Tetravalent Dengue Vaccine | — | — | — | — | — | 4 | |
| HYQVIA | — | — | — | — | 3 | ||
| Ponatinib | — | — | — | — | 3 | ||
| Carboplatin | — | — | — | — | — | 2 | |
| VONVENDI | — | — | — | — | — | 1 | |
| IGI, 10% | — | — | — | — | — | 1 | |
| TAK-928 | — | — | — | — | — | 1 | |
| Control Arm | — | — | — | — | — | 1 | |
| Epoetin Alfa | — | — | — | — | — | 1 | |
| Upadacitinib | — | — | — | — | — | 1 | |
| Active Comparator | — | — | — | — | — | 1 |
39 more active programs hidden
Next readouts
- 2020-05-05
- 2021-11-08
- 2022-08-12
- 2024-06-16
- 2025-04-16
- 2025-04-27
- 2025-05-30
- 2025-10-15
- 2026-06-25
- 2026-07-31
Top conditions
- Healthy Volunteers86
- Diabetes Mellitus51
- Crohn's Disease36
- Type 2 Diabetes Mellitus34
- Hypertension32
- Colitis, Ulcerative26
- Crohn Disease24
- Ulcerative Colitis21
Frequently asked questions about Takeda
- How many clinical trials does Takeda have on ClinicalTrials.gov?
- Takeda is listed as the lead sponsor on 1,019 clinical trials in ClinicalTrials.gov, 127 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Takeda's trials are in Phase 3?
- 331 of Takeda's trials are in Phase 3, spread across 79 active drug programs.
- What therapeutic areas does Takeda focus on?
- Takeda's most-studied conditions on ClinicalTrials.gov are Healthy Volunteers, Diabetes Mellitus, Crohn's Disease, Type 2 Diabetes Mellitus, Hypertension.
- When are Takeda's next clinical trial readouts?
- Takeda has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma”, expected around 2020-05-05.